Background Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a
broad range of Gram-negative bacteria. In this study, Day 14 all-cause mortality (ACM) rates …

Objective To collate the clinical response and pathogen eradication rates for meropenem
monotherapy with in vitro susceptibility of the causative pathogens. Methods Data were …

Sir, Extracorporeal membrane oxygenation (ECMO) is a supportive therapy and definitive
management often relies on adequate drug therapy aimed at reversing the underlying cause …

Purpose Critically ill patients with preserved or increased renal function have been shown to
be at risk of underexposure to meropenem. Although many meropenem population …

Purpose. The clinical and economic outcomes of a meropenem dosage strategy based on
pharmacodynamic concepts are retrospectively reviewed. Methods. The medical records of …

Pseudomonas aeruginosa pneumonia remains a difficult therapeutic problem. Optimal
doses and modes of administration of single agents often do not result in acceptable …

Objectives To describe the interstitial fluid (ISF) and plasma pharmacokinetics of
meropenem in patients on continuous venovenous haemodiafiltration (CVVHDF). Patients …

Background and objective: Meropenem is a carbapenem antibacterial frequently prescribed
for the treatment of severe infections in critically ill patients, including those receiving …

Use of high ultrafiltrate flow rates with continuous venovenous hemofiltration (CVVHF) in
critically ill patients is an emerging setting, for which there are few data to guide drug dosing …

Background Sepsis and bacterial meningitis are major causes of mortality and morbidity in
neonates and infants. Meropenem, a broad-spectrum antibiotic, is not licensed for use in …